Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4212396 | 0.98 | TSHR (0.53) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL4210618 | 0.96 | TSHR (0.52) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL4208157 | 0.96 | TSHR (0.52) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL29381574 | 0.87 | TSHR (0.47) | TSHRLMNATDP1HSD17B10ALOX15 | |
| SCHEMBL9768560 | 0.87 | TSHR (0.47) | TSHRLMNATDP1HSD17B10ALOX15 | |
| SCHEMBL3677102 | 0.84 | ALOX5 (0.44) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL5662234 | 0.81 | TSHR (0.60) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL28317206 | 0.81 | TDP1 (0.51) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL3908136 | 0.80 | LMNA (0.68) | TSHRLMNATDP1HPGDHSD17B10 | |
| SCHEMBL29525350 | 0.80 | LMNA (0.68) | TSHRLMNATDP1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209642-A1 | Hydroxy Acid Complexes for Antiaging and Skin Renovation | BIODERM RESEARCH (US) | 2009-08-20 | — | — | US | claimed |
| US-7427690-B2 | Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration | BIODERM RESEARCH (US) | 2008-09-23 | — | — | US | claimed |
| US-20070099886-A1 | Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration | BIODERM RESEARCH (US) | 2007-05-03 | — | — | US | claimed |
| US-20260102355-A1 | ORAL PREPARATION COMPRISING CHICORY DIETARY FIBER OR CASSAVA STARCH | LG H&H CO., LTD. (KR) | 2026-04-16 | — | — | US | disclosed |
| CN-119855582-A | Oral formulations comprising chicory dietary fiber or tapioca starch | 株式会社LG生活健康 | 2025-04-18 | — | — | CN | disclosed |
| WO-2024147490-A1 | ORAL PREPARATION COMPRISING CHICORY FIBER OR CASSAVA STARCH | 주식회사 엘지생활건강 | 2024-07-11 | — | — | WO | disclosed |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2021-11-04 | — | — | US | disclosed |
| WO-2020068665-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | FABIUS BIOTECHNOLOGY (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2691077-B1 | SALICYLIC ACID TOPICAL FORMULATION | INTEGUMEN IRELAND LTD (IE) | 2018-05-09 | — | — | EP | disclosed |
| US-20140057976-A1 | USNIC ACID TOPICAL FORMULATION | EVOCUTIS PLC (GB) | 2014-02-27 | — | — | US | disclosed |
| EP-2691076-A1 | USNIC ACID TOPICAL FORMULATION | Evocutis plc (GB) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012172318-A1 | FORMULATIONS CONTAINING TROPOLONOIDS, COPPER SALT AND A SOLVENT SYSTEM | EVOCUTIS PLC (GB) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012164061-A2 | COSMETIC PREPARATIONS AGAINST DANDRUFF | LABORATORIOS MIRET, S.A. (ES) | 2012-12-06 | — | — | WO | disclosed |
| WO-2012131347-A1 | USNIC ACID TOPICAL FORMULATION | EVOCUTIS PLC (GB) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012131348-A1 | SALICYLIC ACID TOPICAL FORMULATION | EVOCUTIS PLC (GB) | 2012-10-04 | — | — | WO | disclosed |
| US-20120189569-A1 | Hydroxy Acid Complexes for Skin Renovation and Clarity | BIODERM RESEARCH (US) | 2012-07-26 | — | — | US | disclosed |
| WO-2011001165-A2 | FORMULATIONS | SYNTOPIX GROUP PLC (GB) | 2011-01-06 | — | — | WO | disclosed |
| US-20090209642-A1 | Hydroxy Acid Complexes for Antiaging and Skin Renovation | BIODERM RESEARCH (US) | 2009-08-20 | — | — | US | disclosed |
| US-7547454-B2 | Hydroxy acid complexes for antiaging and skin renovation | GUPTA SHYAM K | 2009-06-16 | — | — | US | disclosed |
| US-20070092461-A1 | Novel Hydroxy Acid Complexes for Antiaging and Skin Renovation | BIODERM RESEARCH (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189569-A1 | Hydroxy Acid Complexes for Skin Renovation and Clarity | CUTA, TYR, RBP4 | TSHR 1543/4885LMNA 3463/4885TDP1 3675/4885 |
| US-20090209642-A1 | Hydroxy Acid Complexes for Antiaging and Skin Renovation | CUTA, SLC30A6, SLC30A7 | TSHR 2369/4885LMNA 3195/4885TDP1 2757/4885 |
| US-20210338558-A1 | USE OF COLLAGEN BINDING DOMAINS TO DELIVER PRODUCTS TO SKIN | COL14A1, COL2A1, COL1A1 | TSHR 4240/4885LMNA 102/4885TDP1 1677/4885 |
| US-20260102355-A1 | ORAL PREPARATION COMPRISING CHICORY DIETARY FIBER OR CASSAVA STARCH | SI, TAS2R41, TAS2R14 | TSHR 3571/4885LMNA 156/4885TDP1 4476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.